On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. is opening in Suzhou. Within PPD’s 67,000-square-foot (6,224-square-meter) facility, NeoGenomics will maintain a dedicated laboratory and additional shared lab operational space.

The NeoGenomics laboratory will support Greater China-focused clinical trials and testing for global and local Chinese pharmaceutical companies. The NeoGenomics research facility will be operational in 2021.